The Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market is expected to reach $9.5 billion by 2020, at a CAGR of 9% during the forecast period 2022-2028. Castration-resistant prostate cancer (CRPC) or hormone refractory prostate cancer (CRPC) is a type of prostate cancer that recurs after administration of androgen deprivation therapy (ADT) and is gaining prominence […]
